Today: 15 May 2026
TD Securities Filing Throws Spotlight on GCT Semiconductor (GCTS), Raises Flags About 5G Chip Scale-Up and Liquidity
15 May 2026
2 mins read

TD Securities Filing Throws Spotlight on GCT Semiconductor (GCTS), Raises Flags About 5G Chip Scale-Up and Liquidity

San Jose, California, May 15, 2026, 14:02 PDT

TD Securities (USA) LLC reported a 4.6% stake in GCT Semiconductor Holding, Inc., according to a Schedule 13G/A filed Friday. That’s 3,456,392 shares—all but a sliver linked to warrants, the filing said. The update comes as investors continue to watch if the small-cap chip designer’s 5G pipeline is shifting out of test mode into actual shipments.

Why it matters now: GCT reported this week it shipped 3,000 5G chipsets during the first quarter, a 58% jump over the previous three months, and stuck to its outlook calling for quarterly 5G shipment gains through 2026. Notable, given first-quarter sales still came in at just $1.9 million.

Trading picked up in GCT shares, which changed hands at $1.83 Friday afternoon. That price gives the company a roughly $121 million market value, market data show.

TD’s filing stands out for its structure. Warrants attached give holders the choice to pick up shares at $11.50—out of the money as of Friday’s close. TD’s direct common share tally barely hits 3,997, but if you add in the warrants, another 3.45 million shares could come into play.

The filing also noted the securities were picked up as part of regular business activities, not as a play to shake up or steer control at GCT. In short, it’s a standard disclosure, not activist maneuvering.

Earnings season is just getting underway. GCT reported revenue climbing to $1.92 million, up from $496,000. Net loss, though, expanded to $9.86 million from $6.97 million. Operating loss improved a bit, narrowing to $6.13 million compared with $7.74 million.

Chief Executive John Schlaefer said GCT “entered a new phase defined by increasing customer shipments” in the quarter. Chief Financial Officer Edmond Cheng described the period as a “meaningful step,” though he emphasized that results “remain modest” compared to the company’s mid- and long-term targets. Business Wire

Caution is understandable here. In its 10-Q, GCT recorded a modest $100,000 in 5G platform product sales for the quarter, compared with $1.4 million from 5G service revenue. Service fees tend to fluctuate, leaving the company’s push toward more reliable product income as the key hurdle.

In a sponsored note dated May 14, Lisa Thompson at Zacks Small-Cap Research forecasted the sequential ramp would push ahead, predicting “more sales of products and fewer of services.” She tagged the stock with a $4.40 valuation, tying that number to a 2027 revenue estimate of $95 million. It’s worth noting: Zacks SCR discloses that it gets paid by issuers for research coverage.

The landscape is ruthless. Back in February, Zacks called Qualcomm the dominant force in the same segment GCT is aiming for, and described GCT as one of just a handful of companies that could supply those specific 4G and 5G telecom and IoT device needs — though this doesn’t include the majority of smartphones. So GCT is limited to chasing after more niche design wins, rather than challenging the handset modem giants head-on.

Satellite connectivity factors heavily here. GCT, on May 7, announced a reference platform deal with one of the biggest names in satellite communications—a move that builds on a licensing pact struck in January and aims to accelerate next-gen equipment. The customer wasn’t identified, but Schlaefer called the agreement proof of the partner’s “trust” in GCT tech. Business Wire

The real challenge sits on the balance sheet. As of March 31, GCT reported just $7.2 million in cash and cash equivalents, stacked up against $52.1 million in borrowings set to come due within a year. Management flagged the urgent need to deliver positive cash flow, secure fresh capital, and work out new terms with creditors. “Substantial doubt” hangs over GCT’s ability to keep operating, the company admitted. SEC

Further fundraising poses dilution risk for shareholders. GCT warned that more sales of stock, convertible notes, or warrants might erode current owners’ stakes. The company’s 10-Q also showed $7.4 million in cash burned through operating activities during Q1.

For now, it’s not TD’s holding that’s driving the stock—the focus is execution: locking in new 5G product orders, getting more satellites shipped in the back half, and managing the money side without sacrificing big gains. The 13G/A brings another holder into the mix, but the uncertainty about the ramp remains.

Stock Market Today

  • Kraken Parent Payward Lays off 150 Employees Ahead of IPO
    May 15, 2026, 5:34 PM EDT. Kraken's parent company, Payward, is laying off approximately 150 employees, about 5% of its 3,000-strong workforce, as it prepares for an anticipated initial public offering (IPO). The layoffs, described as an optimization exercise, aim to present a leaner, more profitable company to potential investors. Payward had confidentially filed an S-1 registration with the SEC in November but paused IPO plans due to challenging market conditions. The company now plans to revive the process when conditions improve. Concurrently, Payward is expanding strategic collaborations, notably with Franklin Templeton, to develop blockchain-based investment products, and has applied for a national trust company charter with the Office of the Comptroller of the Currency.

Latest articles

Tonix Pharmaceuticals Stock Jumps as Lyme Disease Antibody Data Put 2027 Trial in Focus

Tonix Pharmaceuticals Stock Jumps as Lyme Disease Antibody Data Put 2027 Trial in Focus

15 May 2026
Tonix Pharmaceuticals filed new Phase 1 modeling data showing its experimental Lyme disease antibody, TNX-4800, could maintain serum levels above a proposed protective threshold for six months with a two-dose regimen. Shares rose $1.65 to $15.74 Friday. The company plans a Phase 2 trial in 2027, pending FDA agreement. No Lyme vaccine is currently available in the U.S.
AXT Stock’s AI Rally Hits Governance Snag as Annual Meeting Is Pushed to June

AXT Stock’s AI Rally Hits Governance Snag as Annual Meeting Is Pushed to June

15 May 2026
AXT adjourned its 2026 annual meeting after failing to reach a quorum, rescheduling for June 4. The company seeks shareholder approval to raise authorized common shares to 120 million from 70 million. Shares closed at $123.78, up 7.65%, after a volatile session. China’s export controls on indium phosphide remain a key risk for AXT’s business.
Hyperscale Data Climbs on $5 Million Tender Offer; Spotlight Turns to 10-Q

Hyperscale Data Climbs on $5 Million Tender Offer; Spotlight Turns to 10-Q

15 May 2026
Hyperscale Data plans a tender offer to buy up to $5 million of Class A shares at $0.21 each, above the last GPUS trade at $0.146. The company reported a preliminary first-quarter net loss of about $30 million on revenue of $44 million and filed a late notice for its Form 10-Q. The offer is pending board and regulatory approval.
Tonix Pharmaceuticals Stock Jumps as Lyme Disease Antibody Data Put 2027 Trial in Focus
Previous Story

Tonix Pharmaceuticals Stock Jumps as Lyme Disease Antibody Data Put 2027 Trial in Focus

Go toTop